A Phase 3 Clinical Trial for ALS/MND
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease or Motor Neuron Disease (MND) affects the nerves (motor neurones) in the brain and spinal cord that tell your muscles what to do. This means that the messages from these nerves gradually stop reaching the muscles, leading them to weaken, stiffen and waste.
TUDCA-ALS is a European Consortium involving researchers from several countries that aims to find a new treatment to slow down the progress of ALS by conducting a clinical trial to investigate the safety and efficacy (effectiveness) of Tauroursodeoxycholic acid (also known as TUDCA). TUDCA is a molecule that helps to protect motor neurons by camouflaging a stress chemical released within the motor neuron that starts a process that results in cell death.
To date, riluzole is the only one drug licensed within Europe that is used to treat people living with ALS. The TUDCA-ALS consortium aims to find another disease-modifying treatment that can be given to people living with ALS in the fight to slow the progression of the disease.
A European Study
The TUDCA-ALS Consortium is formed by 10 partner organisations that span seven countries across the EU. They are working together to test the safety and efficacy of Tauroursodeoxycholic acid (TUDCA) as a treatment for amyotrophic lateral sclerosis (ALS). Learn more
There will be a number of opportunities to present the work of the TUDCA-ALS Consortium at meetings, conferences and in journals. Copies of any presentations given or scientific papers published will be made available . View more
Support the Project
The TUDCA-ALS partners are in the process of preparing the results for this Phase III clinical trial. Contact us